SecBot SecBot
PRESS-RELEASE ·Filed Apr 24, 2026

SNDX

Syndax Pharmaceuticals, Inc.
NEUTRAL
Impact 1/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release · Earnings

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$21.39
T+0 close · Apr 24, 2026 · via day close
Latest settled
+5.84%
T+60 · $22.64
Vs SPY
+0.76%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 24 $21.39entry
  2. T+1 · 7mo ago −1.82%α −1.99% · $21.00
  3. T+5 · 7mo ago +0.19%α −0.72% · $21.43
  4. T+20 · 6mo ago −7.57%α −11.60% · $19.77
  5. T+60 · 4mo ago +5.84%α +0.76% · $22.64
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Syndax Pharmaceuticals, Inc. announced it will report its Q1 2026 results on April 30, 2026.

Key Facts

  • Syndax Pharmaceuticals, Inc. announced it will report its Q1 2026 results on April 30, 2026.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3280693

US Market Status

Market Closed · Opens in 7h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 24, 2026